Business Wire

Enyx Premieres the First TCP and UDP Offload Engines for Intel Stratix 10 FPGA on REFLEX CES XpressGXS10-FH200G Board


Enyx, a world-class pioneer in ultra-low latency FPGA-based technology and solutions, is pleased to announce its enterprise-class TCP/IP, UDP/IP and MAC network connectivity Intellectual Property (IP) Cores for FPGAs and SoCs support for the high-performance REFLEX CES XpressGXS10-FH200G PCIe Board, which features a Stratix 10 GX FPGA from Intel’s new top-of-the-line 14nm Stratix 10 family

“We are pleased to collaborate with our valued partner REFLEX CES to offer the industry-first TCP and UDP full hardware stacks on Intel’s new, cutting-edge Stratix 10 FPGAs,”says Eric Rovira Ricard, VP Business Development North America at Enyx. “Intel is making FPGA technology ready for data centers, opening new areas for hardware offloading applications in high performance computing, and Enyx is proud to provide the most mature and feature rich network protocol stacks for seamless, FPGA-enabled network connectivity on the latest devices.”

“We are delighted to work with Enyx to offer the best-in-class UDP & TCP IP low latency reference design on our Stratix 10 FPGA board first to market for the Finance and Networking applications, and therefore providing a fast and trusted solution,” said Eric Penain, Chief Business Officer at REFLEX CES.

Enyx nxTCP and nxUDP IP Cores feature full RTL Layers 2,3,4 implementations with integrated 40G/25G/10G/1G MAC, compliant with the IEEE 802.3 standards, supporting ARP, IPv4, ICMP, IGMP and TCP/UDP protocols. nxTCP and nxUDP are designed to work seamlessly on Intel and Xilinx FPGA and SoC designs. Enyx TCP implementation on Intel Stratix 10 GX devices feature latencies of less than 60 ns in transmission and 110 ns in reception and can also manage up to 32,768 TCP sessions in parallel.
REFLEX CES XpressGXS10-FH200G is the first commercially available PCIe board supporting the 14nm Intel Stratix 10 FPGA family. This board includes the biggest 2800 KLE Stratix 10 density for processing intensive and various data algorithms with its mix of memory capabilities in DDR4 and QDR2+, an optical interface capability of 200Gbit via two QSFP28 cages, uses PCIe gen3 x16. A 200Gbit board-to-board interface is provided using a firefly connection. REFLEX CES is an Enyx’ certified board partner.

Starting in 2018, the Intel Stratix 10 version downloadable package will be available and will include a reference design for the REFLEX CES XpressGXS10-FH200G PCIe board.

About Enyx

Enyx is a leading developer and provider of FPGA-based ultra-low latency technologies and solutions. Enyx Technology & Design Services division provides design services and connectivity IP cores for FPGA and SoC, for tailored Smart NICs and Smart Switches.
More information:


REFLEX CES simplifies the adoption of FPGA technology with its leading-edge FPGA-based custom embedded and complex systems. REFLEX CES FPGA network platforms enables better flexibility and ease of programming, offering a faster and most powerful board, and reducing the customer's’ technology risks and time to market.
More information:

Contact information

Jacqueline Genow, +16465132924
Eric PENAIN, +33(0)169870255

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on